Discovery Engine

Wegovy (semaglutide) is a once-weekly GLP-1 receptor agonist approved by the FDA for chronic weight management in adults and adolescents with obesity...

Zepbound (tirzepatide) is a novel, once-weekly injectable dual agonist that activates GIP and GLP-1 receptors, providing synergistic effects on appeti...

Saxenda (liraglutide) is a once-daily GLP-1 receptor agonist originally developed for type 2 diabetes but later approved for chronic weight management...

Contrave (naltrexone/bupropion) is an oral, centrally acting combination medication approved for chronic weight management in adults with obesity or o...

Plenity is an FDA-cleared, orally ingested hydrogel device designed to promote fullness and reduce calorie intake without systemic absorption. Taken b...

Imcivree (setmelanotide) is an MC4R agonist specifically approved for chronic weight management in patients with rare genetic forms of obesity, such a...

Mounjaro (tirzepatide) is an FDA-approved injectable medication developed by Eli Lilly, originally indicated for type 2 diabetes management. As a dual...

Glucagon-like peptide-1 receptor agonists (GLP-1 drugs) have emerged as one of the most significant advances in modern medicine, reshaping how clinici...

In recent years, glucagon-like peptide-1 receptor agonists (GLP-1 drugs) have gained widespread recognition for their ability to manage type 2 diabete...

At a GlanceBoth Wegovy and Ozempic share the same active ingredient: semaglutide.Wegovy is FDA-approved for weight loss, while Ozempic is approved for...